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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal-dominant tumor suppressor gene syndrome that is
characterized by the development of distinctive benign tumors and malformations in multiple organ systems
(N Eng J Med 355:1345-1356, 2006). Cardiac rhabdomyomas are intracavitary or intramural tumors observed in
50–70 % of infants with TSC but only cause serious clinical problems in a very small fraction of these patients
(N Eng J Med 355:1345-1356, 2006; Pediatrics 118:1146-1151, 2006; Eur J Pediatr 153:155-7, 1994); most individuals have
no clinical symptoms and their tumors spontaneously regress. However, despite being clinically silent, these lesions can
provoke arrhythmias and heart failure (Pediatrics 118:1146-1151, 2006; Eur J Pediatr 153:155-7, 1994).
Case presentation: We here report the clinical findings of an infant suffering from TSC complicated with dilated
cardiomyopathy (DCM) after the regression of cardiac rhabdomyomas. Although his tumors improved spontaneously,
tachycardia and irregular heart rate due to frequent premature ventricular and supraventricular contractions persisted
from the newborn period and were refractory to several medications. His cardiomyopathy was suspected to have been
induced by the tachycardia or arrhythmia. We found carvedilol therapy to be safe and highly effective in treating the
cardiomyopathy. To our knowledge, this is the first case report of TSC with DCM after regression of cardiac tumors and
its successful treatment.
Conclusion: The patient’s clinical course suggests that careful life-long disease management is important, even in TSC
patients without apparent symptoms.
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Background
Tuberous sclerosis complex (TSC) is an autosomal
dominant tumor suppressor gene syndrome that is char-
acterized by the development of benign tumors and
malformations in multiple organ systems [1]. Although
cardiac rhabdomyomas are observed in approximately
50–70 % of infants with TSC, most patients exhibit no
clinical symptoms and their tumors spontaneously re-
gress [1–3]. However, such tumors occasionally cause
serious clinical problems, including symptomatic cardiac
failure and several kinds of arrhythmia [2, 3]. We here
report the successful treatment with carvedilol of an
infant with TSC complicated with dilated cardiomyop-
athy (DCM) which might have been induced by
arrhythmia after regression of cardiac rhabdomyomas.
Case presentation
The male patient was born spontaneously at term after
an uneventful pregnancy despite the detection of cardiac
tumors at 36 weeks by fetal echocardiography. After
birth, he was diagnosed as having TSC based on the
diagnostic criteria of white leaf-shaped hypomelanotic
macules, a subependymal nodule, and a retinal hamar-
toma [4]. Multiple intramural cardiac tumors of 5–
25 mm in diameter were found by transthoracic echo-
cardiography (Fig. 1a, b). Soon after birth, the boy exhib-
ited numerous episodes of premature supraventricular
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contractions (PSVC), multifocal premature ventricular
contractions (PVC), and non-sustained ventricular
tachycardia (NSVT). Mexiletine treatment was com-
menced at 1 month of age (Fig. 2a). Since a maximum
NSVT of 14 beats at a rate of 269 bpm was detected by
Holter electrocardiography (ECG) at the age of 5 months,
we added disopyramide to his therapy regime, which re-
sulted in a decline in NSVT frequency. The tumors
gradually diminished in size, but his frequent PSVC and
tachycardia persisted.
At 20 months of age, the patient’s cardiac function was
preserved; echocardiography revealed a left ventricular
end-diastolic diameter (LVDd) of 30.8 mm (Z-score: 0.5)
and a left ventricular fractional shortening (LVFS) of
28 %.
At 23 months of age, he was admitted to our hospital
due to cardiac dysfunction. His body height and weight
were 85 cm (+0.1 SD) and 11.5 kg (+0.1 SD), respect-
ively. Blood pressure was 88/47 mmHg. Heartbeat was
irregular at 134 bpm without extra heart sounds or mur-
murs. Neither hepatomegaly nor pretibial edema was ob-
served. Laboratory data including blood cell counts,
electrolytes, CRP, CK-MB, troponin T, glucose, ammonia,
lactic and pyruvic acid, and thyroid function showed no
abnormalities. However, brain natriuretic peptide (BNP)
and human atrial natriuretic peptide levels were markedly
increased at 619 pg/ml (normal range: < 20 pg/ml) and
654 pg/ml (normal range: < 43 pg/ml), respectively. There
were no significant increases of viral antibody titers in his
serum, including those for the Coxsackie virus, adeno-
virus, or echovirus. His cardiothoracic ratio was 64 % on a
chest radiograph. Twelve-lead ECG revealed irregular
tachycardia (139 bpm) and sporadic PSVC without ST
abnormality or wide QRS duration (Fig. 3). According to
Holter ECG, the patient’s total number of heartbeats
(THB) was 195,807 per day and mean heart rate was
136 bpm. Frequent multifocal PVC (20,883 beats per day;
10.7 % of THB) and PSVC (29,733 beats per day; 15.2 % of
THB) were also noted. Echocardiography revealed cardiac
dilatation and diffuse hypokinesis, LVDd of 45.2 mm
(Z-score: 3.0), and LVFS of 15 % (Fig. 1c). Severe mi-
tral insufficiency caused by the expansion of the mi-
tral annulus was detected as well. His coronary
arteries were normal. Surprisingly, his cardiac tumors
had diminished in size and were recognizable as a small
bright area in the posterior mitral valve (Fig. 1d).
Diuretics and angiotensin converting enzyme inhibitor
were administered as anti-heart failure therapies. To
control tachycardia and reduce afterload on the failing
heart, we also commenced oral administration of carve-
dilol at 0.15 mg/day (0.01 mg/kg/day) that was gradually
increased to 3.0 mg/day (0.3 mg/kg/day) 3 months later.
Although frequent PSVC persisted, the boy’s mean HR
gradually decreased and the incidence of PVC and its
short run became markedly diminished (Fig. 2a). BNP
gradually decreased to within normal range. The
Fig. 1 Echocardiographic findings. At birth, tumors were located on the postero-septal wall of the left ventricle (a, arrow), right ventricular outflow
(b, arrow), and intraventricular septum (b, arrowhead) at birth. At the age of 23 months, 2D echocardiography disclosed an enlarged left ventricle
(c), and M-mode echocardiography revealed poor left ventricular wall contraction (d)
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Fig. 2 a, b Changes in cardiac function before and during treatment with carvedilol. BNP, Brain natriuretic peptide; LVDd, Left ventricular
end-diastolic diameter; LVFS, Left ventricular fractional shortening; HR: Heart rate; PSVC, Premature supraventricular contraction; PVC, Pre-
mature ventricular contraction
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abnormal values of LVFS and LVDd persisted for 1 year
after the initiation of carvedilol treatment, but both pa-
rameters eventually improved to normal levels (34 %
and 35.8 mm [Z-score: 0.8], respectively) by the age of
4 years (Fig. 2b).
Discussion
We here report the clinical findings of an infant boy suf-
fering from TSC complicated with DCM. Although his
tumors regressed spontaneously, tachycardia and heart
rate irregularity due to frequent PSVC and PVC per-
sisted from the newborn period. After the commence-
ment of carvedilol aimed to control heart rate and
reduce afterload in the failing heart, BNP and LV systolic
function improved within months and LV volume recov-
ered slowly over several years.
The most frequent cardiac involvement in TSC is mul-
tiple cardiac rhabdomyomas, which may spontaneously
regress during the first few years. However, TSC is a
known cause of heart failure because of myocardial de-
pression and inflow or outflow obstruction by tumors
[1–3]. TSC is also classified as one of the secondary
causes of cardiomyopathy [5]. Several reports have de-
scribed DCM as a primary cardiac involvement in pa-
tients with TSC [5, 6]. Although 1 case was of TSC and
DCM without cardiac tumors, the cause of the cardio-
myopathy was unknown [6]. Our patient’s cardiac tu-
mors had improved spontaneously by the time of the
appearance of cardiac dysfunction. Differential diagnoses
for his heart failure included myocarditis, coronary ar-
tery abnormality, hormone or metabolic abnormalities,
and mitochondrial disease, but it was ultimately difficult
to pinpoint its precise nature.
TSC-related cardiac rhabdomyomas can combine
with several other kinds of arrhythmias [1–3]. How-
ever, the relationship between tachycardia/arrhythmia
and cardiomyopathy has not been clearly described in
TSC. Here, we consider that tachycardia or arrhythmia
was responsible for the patient’s cardiomyopathy.
Atrial ectopic tachycardia is the most common
arrhythmia in pediatric arrhythmia-induced cardiomyop-
athy (AIC), for which beta-blockers are frequently used
as the first-line therapy [7]. Heart rate irregularity also
occurs in pediatric AIC as salvos of tachycardia inter-
spersed with periods of sinus rhythm [8]. Prior reports
have described weeks to months for LV systolic func-
tional recovery in AIC, and months to years for reverse
remodeling to bring heart rate and rhythm under
control [9, 10].
The relationship between arrhythmia and cardiomyop-
athy can be difficult to characterize because arrhythmias
may exist for years before their recognition and the de-
velopment of cardiomyopathy [8]. Cardiac magnetic res-
onance imaging may help differentiate AIC from DCM;
in many cases, patients with DCM that does not im-
prove exhibit findings in late gadolinium enhancement
suggestive of an underlying scar [11].
As a non-selective beta-blocker with additional vasodi-
lating properties, carvedilol has been demonstrated to
improve survival in adult patients with severe chronic
heart failure [12]. In a multicenter, randomized, double-
blind, placebo-controlled trial by Shaddy et al. [13], car-
vedilol did not significantly affect the primary end point
of composite clinical outcomes in children or adoles-
cents with symptomatic heart failure due to systemic
ventricular dysfunction. However, a prespecified sub-
group analysis noted significant interaction between
treatment and ventricular morphology, indicating a pos-
sible differential effect between patients with a systemic
left ventricle (i.e., beneficial trend) and those whose sys-
temic ventricle was not the left ventricle (i.e., non-
beneficial trend). Other studies have shown carvedilol to
be effective for chronic heart failure in pediatric patients
with systemic left ventricle, such as DCM [14, 15].
Fig. 3 Electrocardiography findings. Twelve-lead electrocardiography (ECG) revealed irregular tachycardia (139 bpm) and sporadic PSVC without
ST abnormality or wide QRS duration
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Additionally, chronic use of a beta-blocker in conjunc-
tion with ACE inhibitor therapy improved clinical status
and exercise tolerance in patients with heart failure [16].
The beta-blocking effects of carvedilol may be important
because catecholamines induce oxidative stress in the
myocardium, and the direct antioxidant effect of this
drug may contribute to oxidative stress relief in the fail-
ing myocardium [15]. Accordingly, carvedilol-mediated
reductions in heart rate and oxidative stress were sus-
pected to have accounted for the improvement in LV
dysfunction in our patient. Special attention must be
paid to the negative inotropic effect of carvedilol during
treatment initiation in patients with severe cardiac dys-
function [14, 17]. We therefore started with a very small
dose, and gradually increased it to avoid any adverse ef-
fects on cardiac function.
Conclusion
To our knowledge, this is the first reported case of an
infant suffering from TSC complicated with DCM after
the regression of cardiac rhabdomyomas whose cardio-
myopathy was suspectedly induced by arrhythmia. We
found that carvedilol therapy was safe and effective for
treating the cardiomyopathy despite the patient’s very
young age. TSC rhabdomyomas generally disappear
spontaneously and have a good prognosis. However, the
present case exhibited heart failure with severely re-
duced LV function during the course of illness, suggest-
ing the importance of meticulous life-long follow-up,
even in apparently asymptomatic patients with TSC.
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